Tax Systems Launches AI-powered, SaaS Solution for Global Pillar Two Compliance and Reporting
15.1.2025 09:00:00 CET | Business Wire | Press release
Secure, scalable software that ensures organisations are prepared for the challenges of OECD Pillar Two rules now and in the future
Tax Systems, the global multi-tax compliance SaaS provider, has today announced the availability of Pillar2, an intuitive solution to de-risk and simplify compliance with the OECD’s global Pillar Two tax rules. Designed for organisations operating across multiple jurisdictions - Pillar2 will save businesses valuable time and reduce the risk of errors, so they can cost effectively operationalise Pillar Two reporting and comply with confidence.
Pillar2 integrates seamlessly with the provisioning and country-by-country reporting applications on TaxSuite - Tax Systems’ modular platform for international tax compliance. This means organisations can upload information once and re-use it as a single source of truth for their tax compliance data - helping to ensure consistency and accuracy across the tax reporting cycle and strengthen tax control frameworks.
The solution offers a range of innovative features, including a jurisdiction implementation tracker that shows if QDMTT, IIR, or UTPR are in force - this is kept up-to-date by Tax Systems, making it easy for organisations to know which rules are applied, and saving them the need to constantly monitor for changes. The offsets and allocations process is automated, with calculations that can’t be overridden, to further de-risk Pillar Two compliance. A comprehensive audit trail logging all user actions and data changes ensures complete transparency.
In addition to offering robust compliance support, Pillar2's flexible data management means it’s easy to upload information from both centralised systems and local operations, saving time, optimising processes and reducing the risk of errors.
Generative AI capabilities within Pillar2 also gives real-time tax insights, helping professionals to proactively manage risks and optimise their tax processes. Users can ask questions about their Pillar Two numbers, using natural language, receiving instant, data-driven responses. This approach makes it easy to identify and investigate any anomalies, while improving tax-related decision-making.
"Pillar Two compliance has added further complexity to tax professionals’ already heavy workloads, but our solution can take some of the burden by calculating any top-up tax due accurately and efficiently,” said Bruce Martin, CEO of Tax Systems. “Pillar2 has been designed from the ground up to help organisations meet these new global tax reporting requirements, simplify compliance processes and provide useful insights. Armed with the ability to manage their entire tax control framework from a single, fully connected platform, organisations can significantly reduce operational complexity while ensuring accuracy in every step of the compliance process.”
Improved collaboration backed by robust security
Pillar2 also supports organisations wishing to take advantage of co-sourcing - its SaaS capabilities, including role-based access control, ensure that only the right people can access sensitive tax data. This means that multi-nationals can maintain a level of control and collaborate with their advisors on different elements of the Pillar Two process using the same solution and data; rather than outsourcing their entire Pillar Two process.
Furthermore, all data is stored securely in MS Azure with a full audit trail, in keeping with being ISO27001 certified. Based on an organisation’s preference, Pillar2 can be configured for data to be hosted in either the UK or EEA.
“We have created a solution that is fit for purpose now and in the future, ensuring compliance with regulations and legislation as it changes both globally and locally,” concludes Bruce Martin. “The tax logic and calculations in Pillar2 have been built by the same team that supports Alphatax – the number 1 corporation tax compliance software in the UK, Ireland, and UAE. This is the latest solution on our global tax compliance and reporting platform and we’re excited for what is still to come. Tax compliance is always evolving and growing in complexity, and we are committed to advancing tax technology and supporting the global tax digitisation agenda.”
To learn more about Pillar2, click here.
About Tax Systems
Tax Systems, a Bowmark Capital-backed investment, is a global multi-tax compliance SaaS provider, with market-leading solutions across the UK, Ireland, Europe and the UAE. Its solutions digitise tax processes and revolutionise compliance operations, enabling tax professionals to create better opportunities and generate valuable insights from their tax function while also mitigating risk. Translating complex, ever-changing tax legislation into intuitive solutions, customers can trust that their calculations will be right, first-time, every time.
Founded in 1991, Tax Systems has over 30 years’ experience and works with over 42% of the FTSE 100 and 80% of the top advisory firms in the UK and Ireland, where more than 30,000 tax professionals are trained to use their solutions, filing over 200,000 submissions every year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115190834/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom